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Abstract
Background: fibroblast  growth  factor  (fGf)  is  in-
volved in skin tumorigenesis: it promotes cell viability,
induces  angiogenesis  and  stimulates  invasiveness.
Dobesilate is a drug that blocks the activity of fGf.
The primary objective was to evaluate the efficacy and
tolerability of potassium dobesilate 5% cream in the
treatment of actinic keratoses.
Methods: Potassium dobesilate 5% cream was applied
twice daily for 16  weeks to actinic keratosis lesions in
30 patients. The lesions were evaluated clinically at an
initial baseline visit, at intermediate visits, and at 16
weeks of treatment.
Results:  The use of potassium dobesilate 5% cream
for 16 weeks induced complete regression in 70% of
evaluated actinic keratoses, corresponding to grade I,
II and III clinical variants, and a partial response (at
least 75% reduction of lesions) in 20% of the cases.
Conclusion: our preliminary trial shows that potassium
dobesilate exerts anti-tumorigenic effects and may play
a useful role in the chemoprevention of skin cancers. 
Key  words:  actinic  keratosis;  Dobesilate;  fibroblast
growth factor.
InTRoDucTIon
actinic  keratoses  (aKs)  are  rough,  scaly  lesions  that
commonly occur on sun-exposed areas of the skin. aK
represents the most common carcinoma in situ of the
skin, showingacontinuously increasing incidence
world  wide[1].  aK  has  been  previously  referred  to  as
preneoplastic lesions, but is nowadays defined as intra  -
epidermal  carcinoma  progressing  towards  invasive
squamous cell carcinoma (scc) [2]. Histologically, aK
lesions are characterized by an epidermal proliferation
of atypical keratinocytes starting from the basal cell lay-
er. according to the epidermal involvement of dyspla-
sia, three subtypes of aK lesions may be differentiated:
in situ scc type aK I (mild), in situ scc type aK II
(moderate) and in situ scc type aK III (severe) [3].
until  now,  the  decision  to  treat  aK  lesions  was
based on cosmetic reasons and to relieve symptoms.
However, a general consensus currently exists to treat
aK lesions for prevention of malignancy and metasta-
sis.  Treatment  options  include  ablative  (destructive)
therapies such as cryosurgery, curettage with electro-
surgery and photodynamic therapy, and topical thera-
pies generally used in patients with multiple lesions. 
for topical treatment, fluorouracil has been a tradi-
tional topical treatment for aK, although imiquimod
5% cream and diclofenac 3% gel are effective alterna-
tive therapies. fluorouracil is useful for treating multi-
ple and subclinical lesions, but a long period is often
required to treat deep and hyperkeratotic aK lesions.
The drug can cause wound infections, ulcers and scar-
ring, and has a reported clearance rate of 50% [4]. Im-
iquimod 5% cream is effective in treating aK, with a
complete  response  reported  in  45-75%  of  patients.
However, during treatment, patients generally present
with adverse events, ranging from redness to hemor-
rhagic  crusted  lesions  [5].  3%  diclofenac  in  2,5%
hyaluronic acid gel is a topical non-steroidal anti-in-
flammatory drug (nsaID) formulation that offers an
effective  approach  to  treat  aK,  showing  complete
healing of aK lesions in 50% of treated lesions [6].
adverse effects associated with topical diclofenac were
pruritus (25% of patients), mild erythema (25%), dry
skin (10%) and rash (2%) [7].
on the basis of the successful therapeutic effect of
dobesilate  in  preclinical  models  of  cancer  and  in  a
case-control study of basal cell carcinoma (bcc) [8],
we investigated - to our knowledge for the first time –
the use of potassium dobesilate 5% cream in the treat-
ment of aK lesions. Dobesilate is a new well-charac-
terized and efficient synthetic fibroblast growth factor
(fGf) inhibitor[9] that has been used for many years
as a vasculotropic agent without any known side ef-
fects.
METHoDs
This open-label trial was conducted to evaluate the ef-
ficacy  and  tolerability  of  potassium  dobesilate  5%
cream in the treatment of patients affected by aKs.
This was a study conducted at a single academic study
center. 
PaTIEnTs anD TREaTMEnT
we enrolled 46 patients (12 women and  34 men) from
64 to 90 years (mean age 76.9 years) with clinical diag-
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(moderate)  and  hyperkeratotic  grade  III  (severe)  ac-
tinic keratoses. all patients signed a written informed
consent before initiating treatment, and the study was
conducted in accordance with the ethical guidelines of
the Declaration of Helsinki.
all patients presented at least, one aK lesion local-
ized on the face (52%) or the scalp (48%). 17.4% of
the  patients  presented  grade  I  aK  lesions,  43.5%
grade II aK lesions and 39.1% presented the most se-
vere variant, grade III aK lesions.
Potassium dobesilate 5% cream was prepared at the
Pharmacy Department of the Hospital universitario
Ram￳n  y  cajal  in  Madrid,  spain.  This  formulation
does not contain any keratolytic agent. Topical treat-
ment was self-applied by the patient twice a day on
aK lesions for 16 weeks.
assEssMEnT
To assess the efficacy of the therapy, we clinically eval-
uated the lesions at an initial baseline visit, at interme-
diate visits, and after 16 weeks (endpoint). for the pri-
mary efficacy variable (complete clearance of lesions),
patients were examined 8 weeks after the end of treat-
ment. cosmetic outcome was assessed by investigators
and was based on the amount of scarring, atrophy, in-
duration, erythema and pigmented change within the
treated  area  in  comparison  with  adjacent,  untreated
skin. It was graded as excellent (no erythema, change
in pigmentation, scarring, atrophy or induration), good
(slight to moderate erythema or change in pigmenta-
tion but no scarring, atrophy or induration), fair (slight
scarring, atrophy or induration) or poor (moderate to
extensive scarring, atrophy or induration).
REsulTs
Twelve patients were lost in follow-up and 4 patients
violated protocol (did not apply cream for 4 weeks or
more). Thirty patients completed the 16 weeks treat-
ment period and 8-week post-treatment follow-up. af-
ter 16-week of treatment there was improvement in
aK lesions. Indeed, potassium dobesilate 5% cream
induced a complete clearance in 21/30 patients (70%);
20% of patients (6/30) had partial response (at least
75% reduction of lesions), and 10% of patients (3/30)
showed less than 75% or no clinical improvement. of
the 21 patients with complete clearance of lesions, the
basal grade of aK was: grade I: 5 patients (23.8%),
grade II: 7 patients (33.3%) and grade III: 9 patients
(42.9%). of the 30 patients who completed the proto-
col,  clearance  according  to  basal  grade  of  aK  was:
grade I: 100% (5/5); grade II: 63.6% (7/11) and grade
III: 64.3% (9/14).
In the 30 patients who completed the protocol, the
clinical response according to aK lesion localization
was; a) face: 11/14 patients (78.6%) showed complete
clearance  and  3/14  patients  (21.4%)  a  partial  clear-
ance; b) scalp: 10/16 patients (62.5%) had a complete
clearance; 4/16 patients (25%) a partial clearance and
in  2/16  patients  (12.5%)  had  no  response.  five  pa-
tients cleared their aK lesions before the end of treat-
ment. figure 1 shows that complete remission was ob-
tained in aK lesions as early as at 15 days and 30 days
of treatment.
In  our  sample,  there  was  an  excellent  post-treat-
ment cosmesis after dobesilate application. none of
the patients abandoned treatment because of side ef-
fects nor did they report any systemic adverse effects
related to the use of the topical formulation of dobe-
silate. In some patients who have completed the study,
local  reactions  have  been  observed  restricted  to  the
aK lesion under treatment and were graded as mild,
moderate or severe by the patient and physician. local
observed effects were pruritus: mild (5/23, 22%) and
stinging: mild (4/23, 17%). one of the patients pre-
sented moderate erythema outside of the aK lesions
at  4  weeks  of  treatment,  an  adverse  reaction  which
completely disappeared at 8 weeks of treatment.
DIscussIon
In order to grow beyond minimal size and to metasta-
size, tumors need to induce the growth of new blood
vessels (angiogenesis)[10]. whereas in normal tissues,
vascular quiescence is maintained by the dominant in-
fluence  of  endogenous  angiogenesis  inhibitors  over
angiogenic stimuli, tumor angiogenesis is induced by
increased  secretion  of  angiogenic  factors  and/or  by
downregulation  of  angiogenesis  inhibitors.  because
angiogenesis occurs in hypertrophic aK and scc [11],
antiangiogenic therapy could be an attractive approach
to treat such malignancies.
Dobesilate  has  been  shown  to  exert  anti-tumori-
genic  effects  through  inhibition  of  fGf  [8,  9,  10].
fGf  participates  in  oncogenesis  by  stimulating  cell
proliferation, survival, invasion and angiogenesis. The
crucial role of fGf in tumor development has been
reported  in  animal  studies  in  which  abrogation  of
fGf  signalling  abolishes  tumor  establishment  and
progression [12]. Thus, inhibition of fGf production
by tumor and endothelial cells could be a putative nov-
el  target  for  cancer  therapy.  furthermore,  fGf  has
been shown to be upregulated in skin cancers [13], and
inhibition of fGf signaling in human melanoma cells
abolished experimental melanoma growth in the rabbit
avascular cornea [14].  In addition, in a case-control
study, topical application of dobesilate showed clinical
efficacy in bcc [9]. aK lesions start as localized clon-
al  expansions  of  ultraviolet  light-damaged  ker-
atinocytes. It is possible that local application of dobe-
silate acts by selectively destroying or reprogramming
them to a more normal pattern of differentiation.This
report supports the use of dobesilate as an antiangio-
genic  agent  to  treat  actinic  keratosis.  our  data  also
suggest  that  dobesilate  may  also  be  used  to  treat  a
broad range of angiogenesis-dependent dermatologi-
cal  conditions,  including  squamous  cell  carcinoma
(scc) and basal cell carcinoma (bcc). 
conclusIons
actinic keratosis (aK) is a squamous cell carcinoma
(scc) in situ, and its eradication is mandatory in af-
fected patients. our clinical experience shows a new
potential  application  of  potassium  dobesilate  5%
cream in the topical treatment of aK lesions. Dobesi-
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Fig. 1. Efficacy of dobesilate in hypertrophic actinic keratosis lesions. Keratotic actinic keratosis in three patients treated with
potassium dobesilate 5% cream twice a day. left panels depict actinic keratosis on the ear of patient nﾺ 3 before (a), at 12 days
(b) and clinical remission of lesion after 15 days of treatment (c). actinic keratotic lesions on the face of patient nﾺ 8 (d,e) and
patient nﾺ 9 (f,g) at baseline (d,f) and after 30 days of treatment (e,g).
5) Cuevas_Umbruchvorlage  14.02.11  14:26  Seite 69late appears to be effective, safe, and well tolerated.
larger placebo-controlled clinical trials are warranted
to compare the effectiveness of this well known anti-
fGf compound in the treatment of aK lesions. How-
ever,  our  preliminary  results  suggest  that  potassium
dobesilate 5% cream may play a key role in the chemo-
prevention of skin cancers, which could have a signifi-
cant public health impact.
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